Denmark offers unique health data and excellent researchers, making the country very attractive for international pharmaceutical companies wanting to conduct clinical research and trials.
The public-private partnership, National Experimental Therapy Partnership (NEXT) who will manage the large grant, is a collaboration across regions, university hospitals, universities and private pharmaceutical companies in Denmark, working to strengthen Denmark as a preferred country for early phase clinical research.
New centres for lung diseases and infectious diseases
Clinical research receives high priority within the Danish healthcare system. Approximately 300 clinical trials are conducted each year, initiated by the industry and researchers respectively. Both types of trials are based on both close and efficient cooperation with hospitals.
The donation now enables the building of two new centres for lung diseases and infectious diseases and an opportunity to significantly increase the volume of early clinical trials in patients.